



---

### INFORMATION DISCLOSURE STATEMENT

---

Please acknowledge receipt of the following by affixing hereon the Patent and Trademark Office date stamp and returning this card to our office.

Applicant(s): Erion, et al. Client: Metabasis Therapeutics, Inc.  
Serial No.: 09/978,454 Filed: October 15, 2001  
Attorney: Lisa M. McGeehan

### NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS

Docket No.: 030727.0027.CON1  
Date of Deposit: January 3, 2002  
Enclosure(s): Transmittal Ltr (1 pg.); Information Disclosure Statement (2 pgs);  
PTO Form 1449 (8 pgs)



Please type a plus sign (+) in this box. → ☒

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	<b>Application Number</b>	09/978,454	
	<b>Filing Date</b>	October 15, 2001	
	<b>First Named Inventor</b>	ERION	
	<b>Group Art Unit</b>	TBA	
	<b>Examiner Name</b>	TBA	
<b>Total Number of Pages in This Submission</b>	11	<b>Attorney Docket Number</b>	030727.0027.CON1

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
<b>Remarks</b>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

<b>Firm or Individual name</b>	Brobeck, Phleger & Harrison LLP
<b>Signature</b>	<i>Risa M. McGehee</i> , Reg. No. 41,185
<b>Date</b>	1-03-2002

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <input type="text"/>			
<b>Typed or printed name</b>	BARBARA J. KIELT	<b>Date</b>	Jan. 3, 2002
<b>Signature</b>	<i>Barbara J. Kielt</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Patent  
030727.0027.CON1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Mark D. Erion, et al.

Serial No.: 09/978,454

Filed: October 15, 2001

For: NOVEL PRODRUGS FOR  
PHOSPHORUS-CONTAINING  
COMPOUNDS

Group Art Unit: TBA

Examiner: TBA

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In compliance with Applicants' duty under 37 CFR 1.56, the following information is brought to the attention of the Examiner. The items listed on the attached Form PTO 1449 were cited in Parent U.S. Patent Application number 09/392,352, filed September 8, 1999. Therefore, copies of the same are not enclosed. Applicants respectfully request that the documents be made of record in the above-referenced application. Applicants also request that the Examiner return an initialed copy of the attached Form PTO 1449 with the next Official Action indicating that the documents have been considered.

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

January 3, 2002  
Date of Deposit

BARBARA J. KIELT  
Name of Person Mailing Paper  
Barbara J. Kielt  
Signature of Person Mailing Paper

Information Disclosure Statement  
Serial No.: 09/978,454  
Page 2 of 2

This Information Disclosure Statement is believed to be timely in that it is being submitted under 37 CFR 1.97(b)(3) before the mailing of a first Office Action on the merits, whereby no fee is required. However, if counsel for Applicant is in error in this regard, the Commissioner is authorized to charge any required fee to counsel's Deposit Account No. 50-1273.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON LLP

Dated: 1-03-2002

By: Lisa M. McGeehan  
Lisa M. McGeehan  
Reg. No. 41,185

**BROBECK, PHLEGER & HARRISON LLP**  
12390 El Camino Real  
San Diego, CA 92130-2081  
Telephone: (858) 720-2500  
Facsimile: (858) 720-2555

**LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION & DISCLOSURE STATEMENT**

(Use several sheets if necessary)

ATTY. D. 7 NO.

SERIAL NO.

030727.0027.CON1

09/978,454

APPLICANT:

ERION

FILING DATE:

10/15/01

GROUP:

TBA

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA	3,018,302 A	01.23.62	Bielefeld, <i>et al.</i>			
	AB	5,658,889	08/19/97	GRUBER, <i>et al.</i>	514	43	12/14/94

**FOREIGN PATENT DOCUMENTS**


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS-	SUB CLASS	TRANSLAT	
							YES	N
	AC	91 19721 A1	12/26/91	WO				
	AD	98 39344 A	11/09/98	WO				
	AE	98 39343 A	11/09/98	WO				
	AF	98 39342 A	11/09/98	WO				
	AG	0 180 276 A1	05/07/86	EP				
	AH	3512781 A1	04/10/85	DE				
	AI	0 353 692 B1	07.02.90	EPO				
	AJ	WO 96/01267 A	18.01.96	WO				
	AK	0 161 955 A	21.11.85	EPO				
	AL	WO 97/03679 A	06.02.97	WO				
	AM	0 338 372 A	25.10.89	EPO				
	AN	0 481 214 A	22.04.92	EPO				

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

OTHER DOCUMENTS (Including Author, Title, Date, and Relevant Pages, etc.)



AO	Alexander, et al., "Preparation of 9-(2- Phosphonomethoxyethyl) Adenine Esters as Potential Prodrugs," Collect. Czech, Chem Commun., 59: 1853-1869 (1994)
AP	Amin, et al., "1-Hydroxy-3-(methylpentylamino)-propylidene-1, 1-bisphosphonic Acid as a Potent Inhibitor of Squalene Synthase," Arzneimittelforschung. 46(8): 759-762 (1996)
XA	Atiq, O.T., et al., "Treatment of Unresectable Primary Liver cancer With Intrahepatic Fluorodeoxyuridine and Mitomycin C Through an Implantable Pump," <u>Cancer</u> , 69, 920-924 (1992)
AQ	Auberson, et al., "N-Phosphoalkyl-5-Aminomethylquinoxaline-2,3-Diones: <i>In Vivo</i> Active Ampa and NMDA(Glycine) Antagonists," Bioorg. Med. Chem. Lett., 9: 249-254 (1999)
AR	Balthazor, et al. "Nickel-Catalyzed Arbuzov Reaction: Mechanistic Observation," <u>J. Org Chem.</u> , 45: 5425-5426 (1980)
XB	He, et al., "Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice," <u>Chem Res. Toxicol</u> 1998, 11, 252-259
AS	Bespalov, et al., "Prologation of morphine analgesia by competitive NMDA receptor antagonist D-CPPene (SDZ EAA 494) in rats," <u>Eur. J. Pharmacol.</u> 351: 299-305 (1998)
AT	Bijsterbosch, et al., "Disposition of the acyclic Nucleoside Phosphonate (S)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl) Adenine," <u>Antimicrobial Agents and Chemotherapy</u> . 42(5): 1146-1150 (1998)
AU	Bird, et al., "Synthesis of Novel N-Phosphonoalkyl Dipeptide Inhibitors of Human Collagenase," <u>J. Med. Chem.</u> 73: 158-169 (1994)
AV	Brill and Landon, et al., <u>Chem Rev.</u> , 84: 577-585 (1984)
AW	Campagne, et al. "Synthesis of Mixed Phosphate Diester Analogues of Dipeptides using BOP or PyBOP Reagents," <u>Tetrahedron Lett.</u> , 34(42): 6743-6744 (1993)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

**OTHER DOCUMENTS (Including Author, Title, Date, and Relevant Pages, etc.)**

AX	Campbell, "The Synthesis of Phosphonate Esters, an Extension of the Mitsunobu Reaction," <u>J. Org. Chem.</u> 52: 6331-6335 (1992)
AY	Casara, <i>et al.</i> , "Synthesis of Acid Stable 5'-o-Fluoromethyl Phosphonates of Nucleosides," <u>Bioorg. Med. Chem. Lett.</u> , 2(2): 145-148 (1992)
AZ	Casteel, <i>et al.</i> , "Steric and Electronic Effects in the Aryl Phosphate to Arylphosphonate Rearrangement," <u>Synthesis</u> , 691-693 (1991)
XC	Chen, <i>et al.</i> , "Sensitization of Human Breast Cancer Cells to Cyclophosphamide and Ifosfamide by Transfer of a Liver Cytochrome P450 Gene," <u>Cancer Research</u> , 56, 1331-1340 (1996)
XD	Chen and Waxman "Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a Combined chemotherapy/Cancer Gene Therapy Strategy," <u>Cancer Research</u> , 55, 581-589 (1995)
BA	De Lombaert, <i>et al.</i> , "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors" <u>J. Med. Chem.</u> 37: 498-511 (1994)
BB	De Lombaert, <i>et al.</i> , "Pharmacological profile of a Non-Peptidic Dual Inhibitor of Neutral Endopeptidase 24.11 and Endothelin-converting enzyme," <u>Biochem Biophys Res Commun.</u> 204: 407-412 (1994)
BC	De Waziers, <i>et al.</i> , "Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues," <u>J. Pharm. Exp. Ther.</u> 253: 387-394 (1990)
BD	Dearfield, <i>et al.</i> , "Analysis of the Genotoxicity of Nine Acrylate/Methacrylate Compounds in L5178Y Mouse Lymphoma Cells," <u>Mutagenesis</u> 4: 381-393 (1989)
BE	Desos, <i>et al.</i> , "Structure-Activity Relationships in a Series of 2(1H)-Quinolones Bearing Different Acidic Function in the 3-Position: 6,7-Dichloro-2(1H)-oxoquinoline-3-phosphonic Acid, a New Potent and Selective AMPA/Kainate Antagonist with Neuroprotective Properties," 39: 197-206 (1996)
BF	Dickson, <i>et al.</i> , "Orally Active Squalene Synthase Inhibitors: Bis((acyloxy)alkyl) Prodrugs of the $\alpha$ -Phosphonosulfonic Acid Moiety," <u>J. Med. Chem.</u> 39: 661-664 (1996)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

OTHER DOCUMENT (Including Author, Title, Date, and Page Count, etc.)		
BG		Edmunson, <i>et al.</i> , "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of <i>cis</i> -2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," <i>J. Chem. Res. Synop.</i> , 5: 122-123 (1989)
BH		Enriquez, <i>et al.</i> , "Conjugation of Adenine Arabinoside 5'-Monophosphate to Arabinogalactan: Synthesis, Characterization, and Antiviral Activity," <i>Bioconjugate Chem.</i> 6: 195-202 (1995)
BI		Farquhar, <i>et al.</i> "Biologically-Cleavable Phosphate Protective Groups: 4-Aciox-1,3,2-Dioxaphosphorinanes as Neutral Latent Precursors of Dianionic Phosphates," <i>Tetrahedron Lett.</i> , 36(5): 655-658 (1995)
BJ		Farquhar, <i>et al.</i> , "Biologically Reversible Phosphate-Protective Groups," <i>Journal of Pharmaceutical Sciences</i> 72(3): 324-325 (1983)
BK		Farquhar, <i>et al.</i> , "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2-oxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2-dioxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[β-D-Arabinofuranosyl]adenine 5'-Monophosphate," <i>J. Med. Chem.</i> 28: 1358-1361 (1985)
BL		Farquhar, <i>et al.</i> , "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," <i>J. Med. Chem.</i> 26: 1153-1158 (1983)
BM		Fiume, <i>et al.</i> , "Inhibition of Hepatitis B Virus replication By Vidarbine Monophosphate Conjugated with Lactosaminated Serum Albumin," <i>The Lancet</i> 13-15 (1988)
BN		Freed, <i>et al.</i> , "Evidence for Acyloxymethyl Esters of Pyrimidines, 5'-Deoxyribonucleotides as extracellular sources of active α5'-deoxyribonucleotides in cultured cells," <i>Biochemical Pharmacology</i> , 38(19): 3193-3198 (1989)
BO		Guida, <i>et al.</i> , "Structure-Based Design of Inhibitors of Purine Nucleoside Phosphorylase. 4. A Study of Phosphate Mimics," <i>J. Med. Chem.</i> 37: 1109-1114 (1994)
BP		Hirayama, <i>et al.</i> , "Structure and conformation of a novel inhibitor of angiotensin I converting enzyme – a tripeptide containing phosphonic acid," <i>Int. J. Pept. Protein Res.</i> 38: 20-24 (1991)
BQ		Hunston, <i>et al.</i> , "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," <i>J. Med. Chem.</i> 27: 440-444 (1984)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	



OTHER DOCUMENTS (Including Author, Title, Date, and Page Numbers, etc.)

BR	Keenan, et al., "Pathology Reevaluation of the Kociba et al. (1978) Bioassay of 2,3,7,8-TCDD: Implications for Risk Assessment," J. Tox. Envir. Health 34: 279-296 (1991)
BS	Kelley, et al., "[[(Guaninylalkyl) phosphinico] methyl] phosphonic Acids. Multisubstrate Analogue inhibitors of Human Erythrocyte Purine Nucleoside Phosphorylase," J. Med. Chem. 38: 1005-1014 (1995)
BT	Khamnei and Torrence, "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs," J. Med. Chem. 39: 4109-4115 (1996)
BU	Kryuchkov, et al., Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987)
BV	Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," J. Antimicrob. Chemotherap. 14: 93-99 (1984)
BW	Lu et al., "Palladium-Catalyzed Reaction of Aryl Polyfluoroalkanesulfonates with O,O-Dialkyl Phosphonates Synthesis, 726-727 (1987)
BX	McGuigan, et al., "Kinase Bypass: A new strategy for Anti-Hiv Drug Design," Bioorganic & Medicinal Chemistry Letters, 3(6): 1207-1210 (1993)
BY	Meier, et al., "Cyclic Saligenyl Phosphotriesters of 2',3'-Dideoxy-2'3'-didehydrothymidine (d4t)," Bioorganic & Medicinal Chemistry Letters, 7(2): 99-104 (1997)
BZ	Meijer, et al., "Covalent and Noncovalent Protein Binding of Drugs: Implications for Hepatic Clearance, Storage, and Cell-Specific Drug Delivery," Pharm. Res. 6: 105-118 (1989)
CA	Melvin, "An Efficient Synthesis of 2-Hydroxyphenylphosphonates," Tetrahedron Lett., 22(35): 3375-3376 (1981)
CB	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of Thioinosinic Acid," J. Med. Chem. 22: 811-815 (1979)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

**OTHER DOCUMENTS (Including Author, Title, Date, Page Count, etc.)**

CC	Mitchell, <i>et al.</i> , "Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate," <u>J. Chem. Soc. Perkin Trans. 1</u> 1992
CD	Mitsunobu, "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products," <u>Synthesis</u> , 1-28 (1981)
CE	Moore, <i>et al.</i> , "Comparison of Mutagenicity results for Nine Compounds evaluated at the <i>hprt</i> Locus in the Standard and Suspension CHO Assays," <u>Mutagenesis</u> 6: 77-85 (1991)
XE	Murray, <i>et al.</i> , "Cytochrome P450 Expression is a common Molecular Event in Soft Tissue Sarcomas," <u>J. Pathology</u> , 171, 49-52 (1993)
XF	Murray, <i>et al.</i> , "Cytochrome P450 CYP3A in human renal cell cancer," <u>British J. Cancer</u> , 79, 1836-1842 (1999)
CF	Neidlein, <i>et al.</i> , "Mild Preparation of 1-Benzoyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Diesters and Cyclic Monoester Amides," <u>Heterocycles</u> 35: 1185-1203 (1993)
CG	Nifant'ev, <i>et al.</i> , "Synthesis and Structure of Some Stable Phospholane-Phospholanes," <u>Phosphorus, Sulfur, Silicon and Related Elements</u> 113: 1-13 (1996)
XG	Ogg, <i>et al.</i> , <u>Xenobiotica</u> 29, 269-279 (1999)
CH	Ohashi, <i>et al.</i> , "Synthesis of Phosphonosphingoglycolipid found in Marine Snail Turbo Cornutus," <u>Tetrahedron Lett.</u> , 29(10): 1189-1192 (1988)
CI	Petrakis, <i>et al.</i> , Palladium-Catalyzed Substitutions of Triflates Derived from Tyrosine-Containing Peptides and Simpler Hydroxyarenes Forming 4-(Diethoxyphosphinyl) phenylalanines and Diethyl Arylphosphonates," <u>J. Am. Chem. Soc.</u> , 109: 2831-2833 (1987)
CJ	Redmore, "Phosphorus Derivatives of Nitrogen Heterocycles," <u>J. Org. Chem.</u> , 35(12): 4114-4117 (1970)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

**OTHER DOCUMENTS (Including Author, Title, Date, and Relevant Pages, etc.)**

	CK	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," <u>Pharm. Res.</u> 10 (supp) s24 (1993)
	CL	Shih, <i>et al.</i> , "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," <u>Bull. Inst. Chem. Acad. Sin.</u> 41: 9-16 (1994)
	CM	Turner, "A General Approach to the Synthesis of 1,6-, 1,7-, and 1,8-Naphthyridines," <u>J. Org. Chem.</u> 55(15) (1990)
	XH	Venook, A.P., "Treatment of Hepatocellular Carcinoma: Too Many Options?" <u>J. Clin. Oncol.</u> 12, 1323-1334 (1994)
	CN	Vo-Quang, <i>et al.</i> , "(1-Amino-2-propenyl) Phosphonic Acid, an Inhibitor of Alanine Racemase and D-Alanine:D-Alanine Ligase.," <u>J. Med. Chem.</u> 29(4): 579-581 (1986)
	CO	Wagner, <i>et al.</i> , "Direct Conversion of Tetrahydropyranylated Alcohols to the corresponding Bromides," <u>Tetrahedron Letters</u> 30(5): 557-558 (1989)
	CP	Wallace, <i>et al.</i> , "Design and Synthesis of Potent, Selective Inhibitors of Endothelin-Converting Enzyme," <u>J. Med. Chem.</u> 41: 1513-1523 (1998)
	CQ	Walsh, <i>et al.</i> , "The Structures of Grantianine and Sceleratine," <u>J. Am. Chem. Soc.</u> , 78: 4455-4458 (1956)
	XI	Watkins, <i>et al.</i> , <u>Pharmacogenetics</u> 4, 171-184 (1994)
	CR	Weibel, <i>et al.</i> , "Potentiating Effect of {2-[2-[(2-Amino-1,6-Dihydro-6-oxo-9H-Purin-9-yl)Methyl]-Phenyl]Ethenyl}-Phosphonic Acid (MDL 74,428), A Potent Inhibitor of Purine Nucleoside Phosphorylase, on the Antiretroviral Activities of 2', 3'- Dideoxyinosine Combined to Ribavirin in Mice," <u>Biochem. Pharmacol.</u> 48(2):245-252 (1994)
	CS	Wileman, <i>et al.</i> , "Receptor - mediated endocytosis," <u>Biochem. J.</u> 232: 1-14 (1985)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

**OTHER DOCUMENTS (Including Author, Title, Date, Document Pages, etc.)**

	XJ	Yu, <i>et al.</i> , "In Vivo Modulation of alternative Pathways of P-450-Catalyzed Cyclophosphamide Metabolism: Impact on Pharmacokinetics and Antitumor Activity," <i>J. Pharm. Exp. Ther.</i> 288, 928-937 (1999)
	CT	Zon, "Cyclophosphamide Analogues," <i>Progress in Med Chem.</i> 19: 1205-1246 (1982)
	CU	Predvoditelev D. , <i>et al.</i> , "Glycero-2-hydroxymethylene phosphates" <i>Journal of Organic Chemistry of the USSR (English Translation</i> 13:1489-1492 (1977)
	CV	Predvoditelev, D. <i>et al.</i> , "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" <i>Journal of Organic Chemistry of the USSR (English Translation</i> 17:1156-1165 (1981)
	CW	Hillers, <i>et al.</i> , "Analog of pyrimidinemono- and polynucleotides. VI. Phosphates of 1-(1,4-dihydroxy-2-pentyl) thymine and 1-(1,3-dihydroxy-2-propyl) uracil" 89 (17): 1-264 (1978)
	CX	Farquhar, <i>et al.</i> , "5'-4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorinan -2-y]-2'-deoxy-5-fluorouridine: a membrane permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)" <i>Journal of Medicinal Chemistry</i> 38:488-495 (1995)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant